We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+47.91%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$913M
AUM Growth
-$536M
Cap. Flow
+$46.2M
Cap. Flow %
5.06%
Top 10 Hldgs %
62.91%
Holding
56
New
8
Increased
8
Reduced
5
Closed
3

Top Buys

Rank Stock Value
1
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
+$25.3M
2
SLNO
Soleno Therapeutics
SLNO
+$19.4M
3
CMPS
Compass Pathways
CMPS
+$14.2M
4
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$13.3M
5
APGE icon
Apogee Therapeutics
APGE
+$8.81M

Top Sells

Rank Stock Value
1
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$39.4M
2
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$35.9M
3
ASLN
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
+$5.21M
4
IMUX icon
Immunic
IMUX
+$1.59M
5
CLNN icon
Clene
CLNN
+$1.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.8%
2 Consumer Staples 0.15%
3 Materials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GTH
1
DELISTED
Genetron Holdings Limited ADS
GTH
$105M 11.46%
2,708,058
– –
SLNO
2
DELISTED
Soleno Therapeutics
SLNO
$94.5M 10.36%
+3,203,093
New +$19.4M
HRMY icon
3
Harmony Biosciences
HRMY
$2.07B
$85.4M 9.36%
2,606,247
– –
VRNA
4
DELISTED
Verona Pharma
VRNA
$69.3M 7.59%
4,249,918
– –
AVDL
5
DELISTED
Avadel Pharmaceuticals
AVDL
$42.2M 4.62%
4,096,428
+266,851
+7% +$3.57M
TARS icon
6
Tarsus Pharmaceuticals
TARS
$2.57B
$40.2M 4.4%
2,262,200
– –
SVA
7
DELISTED
Sinovac Biotech, Ltd
SVA
$38.2M 4.18%
5,900,000
– –
GERN icon
8
Geron
GERN
$930M
$35M 3.84%
16,524,634
– –
TERN
9
DELISTED
Terns Pharmaceuticals
TERN
$33.5M 3.67%
6,657,992
– –
GRCL
10
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$31.3M 3.43%
10,881,144
+6,911,717
+174% +$25.3M
VRDN icon
11
Viridian Therapeutics
VRDN
$2.15B
$25.7M 2.82%
1,678,207
– –
OLMA icon
12
Olema Pharmaceuticals
OLMA
$1.01B
$23.1M 2.54%
1,873,704
+534,433
+40% +$5.45M
COGT icon
13
Cogent Biosciences
COGT
$6.95B
$21.9M 2.4%
2,244,941
– –
ALXO icon
14
ALX Oncology
ALXO
$268M
$20.3M 2.22%
4,220,048
– –
ACLX
15
DELISTED
Arcellx
ACLX
$18.1M 1.98%
503,565
+69,780
+16% +$2.41M
VTYX
16
DELISTED
Ventyx Biosciences
VTYX
$14.7M 1.61%
422,075
– –
RYZB
17
DELISTED
RayzeBio, Inc. Common Stock
RYZB
$14.1M 1.54%
+633,576
New +$13.3M
ICVX
18
DELISTED
Icosavax, Inc. Common Stock
ICVX
$13.2M 1.45%
1,704,568
– –
ATXS
19
DELISTED
Astria Therapeutics
ATXS
$12.5M 1.37%
1,681,199
– –
VSTM icon
20
Verastem
VSTM
$547M
$12.5M 1.37%
1,538,461
– –
CMPS
21
Compass Pathways
CMPS
$1.46B
$11.9M 1.3%
+1,608,000
New +$14.2M
ZLAB icon
22
Zai Lab
ZLAB
$2.1B
$11.1M 1.21%
454,606
+9,101
+2% +$242K
ALPN
23
DELISTED
Alpine Immune Sciences Inc
ALPN
$10.5M 1.15%
914,913
– –
CRNX icon
24
Crinetics Pharmaceuticals
CRNX
$8.88B
$10.4M 1.14%
+350,000
New +$7.21M
DYN icon
25
Dyne Therapeutics
DYN
$4.28B
$9.27M 1.02%
1,035,136
+457,494
+79% +$4.93M
1
2 3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM

Vivo Capital's Q3 2023 Portfolio in Review

As of Q3 2023, Vivo Capital held 56 positions worth $913M, down 37% from $1.45B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Vivo Capital deployed $46.2M of net new capital in Q3 2023, opening 8 new positions and adding to 8 existing holdings. Its largest new stake was Soleno Therapeutics: 3,203,093 shares worth $94.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Consumer Staples and Materials.

On the sell side, the largest reduction was ASLAN Pharmaceuticals Limited American Depositary Shares, an estimated $5.21M trimmed.

  • Vivo Capital's largest Q3 2023 buy was Soleno Therapeutics: 3,203,093 shares worth $94.5M.
  • Vivo Capital added most to Gracell Biotechnologies Inc. American Depositary Shares in Q3 2023, an estimated $25.3M increase.
  • Vivo Capital's biggest Q3 2023 reduction was ASLAN Pharmaceuticals Limited American Depositary Shares, cutting an estimated $5.21M.
  • Vivo Capital fully exited VectivBio Holding AG Ordinary Shares in Q3 2023, selling an estimated $39.4M.
  • Vivo Capital's ten largest holdings make up 63% of its $913M portfolio in Q3 2023.
  • Vivo Capital opened 8 new positions and closed 3 in Q3 2023.
  • Vivo Capital's portfolio value fell 37% quarter-over-quarter to $913M.

Based on Vivo Capital's 13F filing for Q3 2023, filed 8 Nov 2023.